These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34970734)

  • 1. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
    Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L
    Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Tsaur G; Popov A; Riger T; Kustanovich A; Solodovnikov A; Shorikov E; Demina A; Verzhbitskaya T; Streneva O; Makarova O; Lapotentova E; Aleinikova O; Miakova N; Boichenko E; Kondratchik K; Ponomareva N; Karachunskiy A; Roumiantsev A; Fechina L
    Br J Haematol; 2021 Jun; 193(6):1151-1156. PubMed ID: 33583020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Fominikh V; Verzhbitskaya T; Riger T; Demina A; Shorikov E; Kustanovich A; Movchan L; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Solodovnikov A; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29860. PubMed ID: 35713168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I investigate minimal residual disease in acute lymphoblastic leukemia.
    Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
    Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia.
    Semchenkova A; Zhogov V; Zakharova E; Mikhailova E; Illarionova O; Larin S; Novichkova G; Karachunskiy A; Maschan M; Popov A
    Int J Lab Hematol; 2023 Aug; 45(4):506-515. PubMed ID: 36871952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
    Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
    Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
    Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
    Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.